SBIR/STTR Research Award
Hematopoietic Support by Adipose-Derived Stromal Cells
Award amount
$100,000Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ARTECEL SCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Bone marrow transplantation requires large numbers of pluripotent hematopoietic
stem cells to achieve a successful clinical outcome. Therefore, there is a pressing
medical need for methods to expand stem cells ex vivo and accelerate their
engraftment in vivo. These steps may be supported by cytokine-producing stromal
cells. The scientists at Artecel Sciences have developed proprietary techniques to
isolate and culture human stromal cells from adipose tissue that can be used for
autologous and allogeneic transplantation. This SBIR investigates the hypotheses
that adipose derived stromal cells will (1) support hematopoietic progenitor cell
proliferation and differentiation in vitro and (2) accelerate their engraftment in vivo.
Aim 1 (Phase I) will demonstrate that human adipose derived stromal cells will
support proliferation of multipotent and pluripotent hematopoietic progenitors in
short and long term cultures using flow cytometric and methylcellulose assays. This
work provides a foundation for Phase H studies to determine: (Aim 3) The ability of
ex vivo expanded hematopoietic progenitors to repopulate sublethally irradiated
NOD/SCID mice; (Aim 4) The ability of adipose derived stromal cells to accelerate
hematopoietic stem cell engraftment in sublethally irradiated NOD/SCID mice.
PROPOSED COMMERCIAL APPLICATION:
This SBIR will develop technology with application to all patients receiving bone
marrow transplantation. Each year, 20,000+ patients under this therapy at an
individual cost of $100,000. Artecel Sciences technology has the potential to
significantly reduce the clinical and financial burden of these procedures.
Technology keywords
Not reported